MINASTRIN 24 FE Drug Patent Profile

When do Minastrin 24 Fe patents expire, and when can generic versions of Minastrin 24 Fe launch?

Minastrin 24 Fe is a drug marketed by Apil and is included in one NDA.

The generic ingredient in MINASTRIN 24 FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for MINASTRIN 24 FE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MINASTRIN 24 FE
What excipients (inactive ingredients) are in MINASTRIN 24 FE?	MINASTRIN 24 FE excipients list
DailyMed Link:	MINASTRIN 24 FE at DailyMed

US Patents and Regulatory Information for MINASTRIN 24 FE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	MINASTRIN 24 FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	203667-001	May 8, 2013		DISCN	Yes	No

Expired US Patents for MINASTRIN 24 FE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	MINASTRIN 24 FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	203667-001	May 8, 2013	5,552,394
Apil	MINASTRIN 24 FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	203667-001	May 8, 2013	6,667,050

MINASTRIN 24 FE: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

MINASTRIN 24 FE, an oral contraceptive, faces a competitive market landscape shaped by evolving regulatory requirements and patent expiries. Analysis indicates a mature product lifecycle with declining sales projections, influenced by generic competition and strategic portfolio shifts by its innovator.

What is the current market position of MINASTRIN 24 FE?

MINASTRIN 24 FE, a combination product containing ferrous fumarate and levonorgestrel/ethinyl estradiol, is positioned within the oral contraceptive market. This segment is characterized by a high degree of competition from both branded and generic manufacturers. The product's formulation offers a specific regimen of active ingredients and an iron supplement, targeting women seeking contraception and iron supplementation. The market penetration of MINASTRIN 24 FE is directly influenced by prescription patterns, payer reimbursements, and the availability of alternative contraceptive methods. As of the latest available data, the product has been on the market for a considerable period, suggesting it is past its peak growth phase.

The United States represents a primary market for MINASTRIN 24 FE. Its prescription volume is a key indicator of its current market share. While exact real-time prescription data is proprietary, market analysis reports for the oral contraceptive sector indicate a steady, albeit slower, growth rate for established products in the face of new entrants and alternative delivery systems.

How are patent protections for MINASTRIN 24 FE impacting its market exclusivity?

The patent landscape for MINASTRIN 24 FE is critical to understanding its market exclusivity and future revenue potential. The primary patents covering the active pharmaceutical ingredients (APIs) and specific formulations have either expired or are nearing expiry in key markets.

• Original Patent Expiry: The foundational patents for the levonorgestrel and ethinyl estradiol combination have long since expired.
• Formulation and Method of Use Patents: Specific patents relating to the unique formulation of MINASTRIN 24 FE, particularly its dosage and the inclusion of ferrous fumarate in a combined pill, would have provided a period of extended exclusivity. These patents are crucial for understanding the timeline of generic entry.
• Generic Entry: The expiry of key formulation patents has opened the door for generic competitors. The first generic versions of MINASTRIN 24 FE began appearing in the market following the expiration of its primary patent protections. This has led to a significant erosion of market share and price compression for the branded product.
• Orange Book Status: The U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) lists patents and exclusivity data for approved drugs. Examining the Orange Book entry for MINASTRIN 24 FE would reveal the specific patent numbers and their expiration dates, providing a definitive timeline for generic competition. For example, if a key formulation patent expired in 2020, generic versions would likely have been available from 2020 onwards.

The absence of robust, unexpired patent protection on the core product significantly limits opportunities for sustained market exclusivity.

What is the financial performance and projected trajectory of MINASTRIN 24 FE?

The financial trajectory of MINASTRIN 24 FE is characterized by a decline in revenue as generic competition intensifies. Innovator companies typically manage such products through lifecycle management strategies, including delisting or focusing on other products in their pipeline.

• Historical Revenue: Specific historical revenue figures for MINASTRIN 24 FE are typically reported within the broader segment of the innovator company's women's health or reproductive health portfolio. For instance, in the peak years of its market exclusivity, MINASTRIN 24 FE likely generated substantial revenue, potentially in the tens of millions of dollars annually, depending on market penetration and pricing.
• Revenue Decline: Post-generic entry, revenue from MINASTRIN 24 FE experiences a sharp decline. This is due to price erosion caused by multiple generic manufacturers competing on cost, and a reduction in market share as prescribers and patients opt for lower-cost generic alternatives.
• Projected Trajectory: Projections for MINASTRIN 24 FE indicate continued revenue decline. The market share held by the branded product will likely diminish further as generic versions become more entrenched. Companies may reduce marketing and promotional spend for such products, further contributing to declining sales. The product's financial contribution is expected to become nominal within the next five years.
• Pricing: The average selling price (ASP) for branded MINASTRIN 24 FE has decreased significantly since the advent of generic competition. Generic versions typically trade at a fraction of the branded price, often 80-90% lower, depending on market dynamics and payer contracts.
• Market Size: The overall oral contraceptive market is substantial, but MINASTRIN 24 FE’s contribution to this market is shrinking. The total addressable market for products with its indication remains large, but MINASTRIN 24 FE’s share of that market is contracting.

Financial performance is also influenced by manufacturing costs, distribution expenses, and any ongoing regulatory compliance costs. As sales volumes decrease, the per-unit cost of production can increase, impacting profitability margins.

Who are the key competitors for MINASTRIN 24 FE?

The competitive landscape for MINASTRIN 24 FE includes both branded and generic oral contraceptives. The primary competitors are other products offering similar efficacy and hormonal profiles for contraception.

• Branded Competitors: Other branded oral contraceptives that offer levonorgestrel and ethinyl estradiol combinations or similar hormonal profiles would be considered direct branded competitors. These may include products from major pharmaceutical companies with strong portfolios in women's health. Examples of such products, though not direct competitors in formulation but in indication, include other birth control pills containing different progestins or varying dosages.
• Generic Competitors: The most significant competition comes from generic versions of MINASTRIN 24 FE. Once patents expire, multiple pharmaceutical manufacturers can produce and market bioequivalent versions of the drug. These generic products are typically offered at lower price points. Key generic manufacturers who enter this space would be considered direct competitors. For example, if Teva Pharmaceuticals or Mylan (now Viatris) launched a generic version, they would become major competitors.
• Alternative Contraceptive Methods: Beyond oral contraceptives, MINASTRIN 24 FE competes with a broad range of contraceptive options, including:
  • Intrauterine Devices (IUDs): Hormonal and non-hormonal IUDs offer long-acting reversible contraception.
  • Implantable Devices: Subdermal implants provide long-term contraception.
  • Injectable Contraceptives: Depo-Provera and similar formulations.
  • Vaginal Rings and Patches: Alternative delivery systems for hormonal contraception.
  • Barrier Methods and Spermicides: Though less effective, these are also part of the overall contraceptive choice landscape.

The competitive intensity is highest from generic manufacturers due to price. The broader contraceptive market competition highlights the need for products to offer distinct advantages beyond just efficacy, such as convenience, side effect profiles, or cost.

What are the regulatory considerations impacting MINASTRIN 24 FE?

Regulatory frameworks significantly influence the lifecycle and market access of pharmaceutical products like MINASTRIN 24 FE.

• FDA Approval and Labeling: The initial FDA approval process, including clinical trials demonstrating safety and efficacy, is a foundational regulatory hurdle. Post-approval, any changes to the manufacturing process, formulation, or labeling require regulatory review and approval. Changes in FDA guidance on drug safety or efficacy standards can also necessitate product reviews or labeling updates.
• Patent Litigation and Exclusivity Rules: Regulatory bodies, particularly the FDA in the U.S., play a role in enforcing patent exclusivities. The Hatch-Waxman Act, for example, governs the approval of generic drugs and provides mechanisms for brand-name manufacturers to defend their patents. Patent litigation surrounding MINASTRIN 24 FE would have determined the precise timeline for generic market entry.
• Post-Market Surveillance: Like all pharmaceuticals, MINASTRIN 24 FE is subject to post-market surveillance requirements. This includes pharmacovigilance for adverse event reporting and potentially post-marketing studies if required by the FDA. Significant adverse event findings could lead to labeling changes, restricted use, or, in rare cases, market withdrawal.
• Generic Drug Approval Pathway: The Abbreviated New Drug Application (ANDA) pathway for generic drug approval requires demonstrating bioequivalence to the reference listed drug. This pathway facilitates the rapid introduction of lower-cost generics once patents expire.
• International Regulations: MINASTRIN 24 FE may also be subject to regulatory approval and oversight in other countries where it is marketed. Requirements vary by jurisdiction (e.g., EMA in Europe, PMDA in Japan), impacting global market access and revenue.
• Reimbursement Policies: While not strictly regulatory approval, payer policies (Medicare, Medicaid, private insurers) heavily influence market access and demand. These policies are often influenced by regulatory classifications and cost-effectiveness evaluations.

The ongoing trend towards increased scrutiny of drug pricing and value by regulatory bodies and payers could also indirectly impact the commercial viability of older products like MINASTRIN 24 FE.

What is the future outlook for products like MINASTRIN 24 FE?

The future outlook for MINASTRIN 24 FE is one of continued decline in revenue and market share. Its lifecycle stage, coupled with market dynamics, dictates this trajectory.

• Dominance of Generics: Generic versions will continue to dominate the market for MINASTRIN 24 FE. The price advantage of generics makes them the preferred option for many payers and patients once brand exclusivity is lost.
• Limited R&D Investment: Innovator companies typically shift R&D investment towards new drug discovery and development rather than maintaining or revitalizing older products facing generic competition. MINASTRIN 24 FE is unlikely to be a focus for significant new clinical development or line extensions.
• Portfolio Management: Pharmaceutical companies manage their product portfolios strategically. Products like MINASTRIN 24 FE, which have become less profitable due to generic competition, are often deprioritized. This can include reduced marketing efforts, discontinuation of specific dosage forms, or eventual delisting from the market if sales fall below a profitable threshold.
• Niche Market Potential: While overall revenue will decline, there may remain a small, persistent market for the branded product driven by physician familiarity, patient preference for the specific brand, or contractual obligations with certain payers. However, this niche is expected to be small.
• Competition from Novel Contraceptives: The market for contraceptives is dynamic, with ongoing innovation in delivery systems and formulations. Newer products with improved convenience, efficacy, or side effect profiles could further erode the market share of older oral contraceptives, including MINASTRIN 24 FE.

The overall trend for established oral contraceptives like MINASTRIN 24 FE, once their patent protection has lapsed, is a transition to a genericized market with declining branded sales.

Key Takeaways

• MINASTRIN 24 FE operates in a mature and highly competitive oral contraceptive market.
• The expiry of its primary patents has led to the introduction of generic versions, significantly impacting market exclusivity and pricing.
• Financial projections indicate a continued revenue decline for branded MINASTRIN 24 FE due to intense generic competition and price erosion.
• Key competitors include numerous generic manufacturers and a wide array of alternative contraceptive methods.
• Regulatory oversight, including patent enforcement and generic drug approval pathways, has defined the product's market exclusivity timeline.
• The future outlook for MINASTRIN 24 FE is characterized by a shrinking branded market share, with generics dominating sales, and a limited likelihood of significant new investment or market expansion.

FAQs

1. When did the primary patents for MINASTRIN 24 FE expire, allowing for generic entry? The expiration dates of patents vary. The foundational patents for its active ingredients, levonorgestrel and ethinyl estradiol, expired years ago. Key patents specifically covering the MINASTRIN 24 FE formulation, which granted its initial market exclusivity, began expiring in the mid-to-late 2010s, paving the way for generic introductions around that period.

2. What is the typical price reduction observed for MINASTRIN 24 FE after generic entry? Following generic entry, the price of branded MINASTRIN 24 FE typically falls by 80% to 90% or more, as generic manufacturers compete on cost to capture market share. The wholesale acquisition cost (WAC) of the branded product is substantially higher than that of its generic equivalents.

3. Are there any ongoing clinical trials or new indications being investigated for MINASTRIN 24 FE? As of current reporting, there are no significant ongoing clinical trials or investigations for new indications for MINASTRIN 24 FE. Investment in research and development for older, genericized products is minimal.

4. Which pharmaceutical companies are currently manufacturing generic versions of MINASTRIN 24 FE? Multiple generic pharmaceutical companies, including but not limited to manufacturers like Teva Pharmaceuticals, Mylan (now Viatris), and Sandoz, are likely to be producing generic versions of MINASTRIN 24 FE, given its widespread use and patent expiry. Specific manufacturers can be identified by checking pharmaceutical databases and pharmacy formularies.

5. What is the current market size for oral contraceptives in the United States? The U.S. market for oral contraceptives is valued in the billions of dollars annually. While MINASTRIN 24 FE's specific contribution has decreased, the overall market remains substantial due to high prescription volumes across a wide range of products and the ongoing demand for effective contraception.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [2] IQVIA Holdings Inc. (Various Years). Pharmaceutical Market Data and Analysis Reports. (Proprietary market research data for pharmaceutical sales, market share, and prescription trends). [3] GlobalData Plc. (Various Years). Pharmaceutical Company and Product Analysis Reports. (Proprietary reports on drug lifecycles, competitive landscapes, and financial forecasts). [4] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-applications-andas [5] Various Pharmaceutical News Outlets and Industry Publications. (Ongoing). Reports on Drug Patent Expirations and Generic Competition. (e.g., Fierce Pharma, Endpoints News, BioSpace).